

May 23, 2022



# Immunovant to Present at the H.C. Wainwright Global Investment Conference on May 25th

NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- **Immunovant, Inc.** (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference, taking place May 23<sup>rd</sup>-26<sup>th</sup>, 2022.

## H.C. Wainwright Global Investment Conference fireside chat details:

Date: Wednesday, May 25<sup>th</sup>, 2022

Time: 12:30 pm Eastern Time

The presentation will be available via webcast and can be accessed at the Webcast: Investor Relations section of the Company's website, located at [www.immunovant.com](http://www.immunovant.com).

## About Immunovant, Inc.

Immunovant, Inc. is a clinical-stage biopharmaceutical company dedicated to enabling normal lives for people with autoimmune diseases. As a leader in FcRn inhibitor technology, we are boldly developing innovative therapies for a range of debilitating autoimmune diseases with significant unmet patient needs. Our investigational compound, batoclimab, is a novel, fully human, monoclonal antibody targeting the neonatal Fc receptor (FcRn). For additional information on the Company, please visit [www.immunovant.com](http://www.immunovant.com).

## Contact:

Tom Dorney, MS, MBA  
Director, Investor Relations & Strategy  
Immunovant, Inc.  
[info@immunovant.com](mailto:info@immunovant.com)



Source: Immunovant